Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatmentBusiness Insider • 02/22/21
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer's DiseaseGlobeNewsWire • 02/22/21
Is Cassava Sciences (SAVA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/18/21
Cassava Sciences Announces Closing of $200 Million Registered Direct OfferingGlobeNewsWire • 02/12/21
Cassava Sciences Seeks $200M From Equity Offering At 15% Discount To Fund Development Of Lead CandidateBenzinga • 02/10/21
Cassava Sciences to offer $200 million of shares priced at $49 each vs. $50.29 at Tuesday's closeMarket Watch • 02/10/21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common StockGlobeNewsWire • 02/10/21
Cassava's stock jumps 18% on plans to initiate late-stage study for Alzheimer's drugMarket Watch • 02/08/21
Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer's DiseaseGlobeNewsWire • 02/08/21
Cassava Bolts To Record High After Alzheimer's Drug Improves CognitionInvestors Business Daily • 02/04/21
Can This Maverick Biotech Become the Frontrunner in the Fight Against Alzheimer's?The Motley Fool • 02/04/21